Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04488-2

In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w

In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.

Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04695-x

A suite of large pre-trained language models accurately extracts computable clinical data from unstructured electronic health records and integrates the findings into knowledge graphs that can facilitate understanding patient trajectories and treatment responses in the real world.